Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hara, R.
Right arrow Articles by Kondo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hara, R.
Right arrow Articles by Kondo, T.
(Chest. 2004;125:340-344.)
© 2004 American College of Chest Physicians

Serum Levels of KL-6 for Predicting the Occurrence of Radiation Pneumonitis After Stereotactic Radiotherapy for Lung Tumors*

Ryusuke Hara, MD; Jun Itami, MD; Takafumi Komiyama, MD; Daiki Katoh, MD and Tatsuya Kondo, MD

* Department of Radiation Therapy and Oncology, International Medical Center of Japan, Tokyo, Japan.

Correspondence to: Jun Itami, MD, Department of Radiation Therapy and Oncology, International Medical Center of Japan, Toyama 1-21-1 Shinjyuku-ku, Tokyo, Japan 162-8655; e-mail: jitami{at}imcj.hosp.go.jp

To determine the usefulness of serum KL-6 levels for predicting the occurrence of radiation pneumonitis (RP) after the application of single high-dose stereotactic radiation therapy for lung tumors, the serum KL-6 levels were measured in 16 patients before irradiation and every 1 or 2 months thereafter. Three of the 16 patients experienced RP of grade 3 severity according to the European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group toxicity criteria. RP occurred 3 months after the completion of radiation therapy in two patients, and 4 months after completion in one patient. RP occurred at significantly increased frequencies in patients with primary lung cancer (p = 0.01) and adenocarcinoma (p = 0.01), and in those undergoing the concurrent irinotecan therapy (p = 0.02). In all 16 patients, the lactate dehydrogenase level remained normal during the follow-up period. In all three of the patients with RP, KL-6 levels increased by > 1.5-fold compared to the pretreatment value and over the cutoff level of 500 IU. The ratio of the increase in serum KL-6 values 2 months after the patient had undergone irradiation showed a significant correlation with the occurrence of RP (p = 0.04). In conclusion, KL-6 is a useful marker for prediction of the occurrence of RP after single, fractional, high-dose stereotactic irradiation of lung tumors.

Key Words: KL-6 • lung tumor • radiation pneumonitis • stereotactic radiotherapy




This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. Menard, D. Johann, M. Lowenthal, T. Muanza, M. Sproull, S. Ross, J. Gulley, E. Petricoin, C. N. Coleman, G. Whiteley, et al.
Discovering Clinical Biomarkers of Ionizing Radiation Exposure with Serum Proteomic Analysis
Cancer Res., February 1, 2006; 66(3): 1844 - 1850.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Chest Physicians.